We performed an interim analysis (n=33, 28 male, 5 female) of ongoing randomized controlled trial of Twin Precision Treatment (TPT): a novel whole-body digital twin enabled precision nutrition for reversing diabetes. We evaluated the glycemic and extra glycemic clinical and biochemical parameters for patients who completed 4 months longitudinal follow up. Mean age and duration of diabetes was 40 (±8.8) and 2.8 (±2.4) years, respectively. 19 and 13 patients achieved initial partial (HbA1c range 5.7-6.4 %) and complete (HbA1c < 5.7%) remission of diabetes, respectively. Statistically significant decrease in HbA1c % of 3.1%, with all achieving less than 7%. Number of patients with microalbuminuria (30-300 mg) at baseline were 7 which changed to 3. All 12 patients on OAD did not need ongoing OAD, 2 patients on insulin did not need it at 90 days. Glycemic and extra glycemic parameters including HOMA2-IR, HOMA2B, FPG, body weight, BMI, blood pressure, liver enzymes (ALT, GGT), hsCRP, LDL-C, HDL-C, triglycerides, and WBC count demonstrated significant improvements (Figure). The initial results are an early indicator for the translation of the scientific rationale for the technological intervention, through digital twin technology, powered by Internet of Things and Artificial Intelligence, as a modality to enable reversal of diabetes.
767-P: Effect of Digital Twin Technology for Remission of Diabetes on the Glycemic and Extra-Glycemic Parameters: Interim Results of the Prospective Randomised Controlled Clinical Trial | Diabetes | American Diabetes Association (diabetesjournals.org)